# Higher Percentage of CD34+ CD38- Cells Detected by Multiparameter Flow Cytometry From Leukapheresis Products Predicts Unsustained Complete Remission in Acute Myeloid Leukemia

> **NCT02842112** · — · COMPLETED · sponsor: **Hospices Civils de Lyon** · enrollment: 123 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **OTHER:** PBSC mobilization and leukapheresis

## Key facts

- **NCT ID:** NCT02842112
- **Lead sponsor:** Hospices Civils de Lyon
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01
- **Primary completion:** 2013-12
- **Final completion:** 2014-05
- **Target enrollment:** 123 (ACTUAL)
- **Last updated:** 2016-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02842112

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02842112, "Higher Percentage of CD34+ CD38- Cells Detected by Multiparameter Flow Cytometry From Leukapheresis Products Predicts Unsustained Complete Remission in Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02842112. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*